Pharma Heads Hope Trust Built Through Pandemic With Policymakers Will Last
Cautious Optimism Over Quicker Access To New Medicines In EU
Executive Summary
The bosses of Bayer and Roche's pharmaceutical divisions – Stefan Oelrich and Bill Anderson – have called on governments in Europe to create a friendlier environment so that the sector and policymakers can continue to work better together post-pandemic.
You may also be interested in...
Pharma Firms Welcome 'Pragmatic' EU Reforms But Concerns Persist
The European parliament has voted for legislation it says will lead to fairer, more accessible healthcare. The continent's drugmakers are still not wholly convinced.
Sector Stalwart Appalled At Lack Of UK Investor Interest In Biotech
Ali Mortazavi, CEO of e-therapeutics, says the RNAi specialist is delisting from AIM and describes the UK markets as “completely broken and closed” to biotech firms.
Novartis Flies The Flag For US Despite More Job Cuts
It is still “a priority country,” the Switzerland-based giant tells Scrip, as around 240 jobs face the axe at Novartis’s development organizational unit across the Atlantic.